Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%
09:25am, Thursday, 06'th Feb 2025
Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.
Has the Bubble Burst for Viking Therapeutics Stock?
08:15am, Thursday, 06'th Feb 2025
The excitement surrounding Viking Therapeutics (VKTX 3.49%) stock has been dying down significantly lately. In six months, the stock has lost more than 40% of its value.
Viking Therapeutics Plummeted 10% On Its Earnings Report. Here's Why.
09:08pm, Wednesday, 05'th Feb 2025
Viking Therapeutics stock plunged late Wednesday on an earnings report that included mostly incremental updates for its weight-loss drugs. The post Viking Therapeutics Plummeted 10% On Its Earnings Re
Viking Therapeutics, Inc. (VKTX) Q4 2024 Earnings Conference Call Transcript
07:21pm, Wednesday, 05'th Feb 2025
Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q4 2024 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Stephanie Diaz - IR Manager Brian Lian - CEO and President Greg Zante - CFO C
Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
04:05pm, Wednesday, 05'th Feb 2025
Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial Evaluating VK2735 in Obesity Under
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
10:30am, Wednesday, 05'th Feb 2025
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
Prediction: This Pharma Stock Will Be the Best Performer in 2025
08:45am, Wednesday, 05'th Feb 2025
Market uncertainty can make nervous investors leery of investing in industries that are more speculative in nature, such as pharmaceuticals and biotechnology.
Viking Therapeutics: Why The Oral VK2735 Phase 2 Readout Could Send The Stock Soaring
03:34am, Wednesday, 05'th Feb 2025
Oral VK2735 is strategically positioned to become a best-in-class oral GLP-1 therapy, with the Phase 2 trial data readout in H2 2025 serving as a critical catalyst. Phase 1 data for VK2735 represents
This Weight Loss Stock Could Soar Over 220%, According to Wall Street. Time to Buy?
06:36am, Sunday, 02'nd Feb 2025
Medications known as glucagon-like peptide 1 (GLP-1) receptor agonists are taking over the healthcare industry. While you may not be familiar with the term "GLP-1," I'd wager you'll recognize some of
Viking Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?
08:21am, Thursday, 30'th Jan 2025
Since VKTX is devoid of marketed drugs, investors will focus on pipeline updates when it reports Q4 results next week.
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025
04:05pm, Wednesday, 29'th Jan 2025
Conference Call Scheduled for Wednesday, February 5 at 4:30 p.m. Eastern Time SAN DIEGO , Jan. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharm
Viking Therapeutics: Investors Meeting Reality Of The Obesity Market
09:15am, Thursday, 23'rd Jan 2025
Viking Therapeutics has promising clinical developments in obesity, NASH/MASH, and X-ALD, but its stock fell 50% due to broader GLP-1 market concerns. Despite Eli Lilly's Q4 miss, the long-term outloo
Why this Weight-Loss Drug Stock Could Gain 200%
07:38am, Thursday, 23'rd Jan 2025
There are several potential challengers to Novo Nordisk and Eli Lilly's obesity drugs, and Jefferies analysts see one as particularly promising.
This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?
04:10am, Wednesday, 22'nd Jan 2025
One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs that's proven to be both efficacious and safe in clinical studies and in t
Viking Therapeutics, Inc. (VKTX) Increases Yet Falls Behind Market: What Investors Need to Know
06:56pm, Tuesday, 21'st Jan 2025
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.87, denoting a +0.67% change from the preceding trading day.
